Clinical · Molecular biology
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis
Summary
This retrospective study, leveraging the phase III SUCCESS-A trial, assessed the prognostic value of tissue-free circulating tumor DNA (ctDNA) detection in patients with early breast cancer. Plasma samples were analyzed approximately two years after adjuvant chemotherapy in 313 patients. ctDNA detection, observed in 5.8% of patients, was strongly associated with a significantly increased risk of distant recurrence and shorter overall survival. ctDNA was detected a median of 7.9 months before recurrence, showing a sensitivity of 73% and a specificity of 99.6% for distant recurrence. These findings suggest that post-treatment ctDNA can stratify patients at high risk of recurrence.
Critical appraisal
Clinical. This retrospective cohort study, derived from a phase III trial (SUCCESS-A), demonstrates that ctDNA detection two years after adjuvant chemotherapy is a powerful prognostic biomarker for early breast cancer. The very high hazard ratios (HR of 33.3 for distant recurrence and 27.3 for overall survival) indicate a strong association with unfavorable clinical outcomes. The high specificity (99.6%) is particularly relevant for avoiding false positives and unnecessary interventions. These findings justify clinical trials aimed at evaluating early interventions in ctDNA-positive patients, potentially within 3-5 years, to alter the natural history of the disease.
Molecular biology. The main discovery is the clinical validation of a prognostic biomarker, ctDNA, detected by a tissue-free epigenomic approach, eliminating the need for initial tumor tissue. The use of a "tissue-free" test like Guardant Reveal is a significant advantage, simplifying logistics. The analysis was performed on plasma samples, a liquid biopsy, which is less invasive and allows for longitudinal monitoring. The sensitivity of 73% and specificity of 99.6% for distant recurrence within one year of sampling indicate good analytical validity for this context. These data pave the way for integrating this type of test into post-treatment surveillance protocols to identify patients requiring therapeutic intensification.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology